Please wait a minute...
文章检索
预防医学  2022, Vol. 34 Issue (3): 253-257    DOI: 10.19485/j.cnki.issn2096-5087.2022.03.008
  综述 本期目录 | 过刊浏览 | 高级检索 |
肠道微生物与糖尿病病理机制研究进展
方媛 综述, 哈小琴 审校
联勤保障部队第九四〇医院检验科,甘肃 兰州 730000
Research progress of intestinal microorganisms and pathogenesis of diabetes mellitus
FANG Yuan, HA Xiaoqin
Clinical Laboratory, The 940th Hospital of Joint Logistics Support Force of Chinese People Liberation Amy, Lanzhou, Gansu 730000, China
全文: PDF(793 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 肠道微生物作为人体最大的微生态系统,参与人体的物质和能量代谢,对人体健康有重大影响。糖尿病易导致肠道微生物丰度失调和组分改变,降低多样性和平衡性引发肠道失调。肠道失调可通过肠道微生物代谢产物减少、炎性反应和胰岛素抵抗等促进糖尿病的发生发展。本文综述肠道微生物通过短链脂肪酸、胆汁酸和脂多糖等代谢产物参与糖尿病发病的机制,以及肠道微生物介导的糖尿病治疗现状,为糖尿病与肠道微生物研究提供理论依据。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
方媛
哈小琴
关键词 肠道微生物糖尿病短链脂肪酸胆汁酸脂多糖益生菌    
Abstract:As the largest human microecosystem, intestinal microorganisms participate in human material and energy metabolisms and pose a significant impact on human health. Diabetes mellitus is likely to cause imbalance of abundance and component alterations in intestinal microorganisms, and reduce the diversity and balance, leading to intestinal microflora dysregulation. It has been shown that intestinal microflora dysregulation may promote diabetes development and progression through the reduction of intestinal microbial metabolites, inflammatory reaction and insulin resistance. This review summarizes the involvement of intestinal microorganisms in the pathogenesis of diabetes through metabolites including short-chain fatty acid, bile acid and lipopolysaccharide, and describes the current status of intestinal microorganisms-mediated treatments for diabetes, so as to provide the theoretical basis for the researches on diabetes and intestinal microorganisms.
Key wordsintestinal microorganism    diabetes mellitus    short-chain fatty acid    bile acid    lipopolysaccharide    probiotic
收稿日期: 2021-09-17      修回日期: 2021-12-27      出版日期: 2022-03-10
中图分类号:  R587  
基金资助:国家自然科学基金(81700272)
作者简介: 方媛,硕士,主要从事肠道微生物研究
通信作者: 哈小琴,E-mail:haxiaoqin2013@163.com   
引用本文:   
方媛, 哈小琴. 肠道微生物与糖尿病病理机制研究进展[J]. 预防医学, 2022, 34(3): 253-257.
FANG Yuan, HA Xiaoqin. Research progress of intestinal microorganisms and pathogenesis of diabetes mellitus. Preventive Medicine, 2022, 34(3): 253-257.
链接本文:  
https://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2022.03.008      或      https://www.zjyfyxzz.com/CN/Y2022/V34/I3/253
[1] World Health Organization.Diabetes[EB/OL].(2021-11-10)[2021-12-27]. https://www.who.int/news-room/fact-sheets/detail/diabetes.
[2] WANG L M,GAO P,ZHANG M,et al.Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013[J].JAMA,2017,317(24):2515-2523.
[3] YEHUALASHET A S,YIKNA B B.Microbial ecosystem in diabetes mellitus:consideration of the gastrointestinal system[J].Diabetes Metab Syndr Obes,2021,14:1841-1854.
[4] TREMAROLI V,BÄCKHED F.Functional interactions between the gut microbiota and host metabolism[J].Nature,2012,489(7415):242-249.
[5] DAVID L A,MAURICE C F,CARMODY R N,et al.Diet rapidly and reproducibly alters the human gut microbiome[J].Nature,2014,505(7484):559-563.
[6] MEHTA R S,ABU-ALI G S,DREW D A,et al.Stability of the human faecal microbiome in a cohort of adult men[J].Nat Microbiol,2018,3(3):347-355.
[7] WANG T Y,ZHANG X Q,CHEN A L,et al.A comparative study of microbial community and functions of type 2 diabetes mellitus patients with obesity and healthy people[J].Appl Microbiol Biotechnol,2020,104(16):7143-7153.
[8] PASCAL V,POZUELO M,BORRUEL N,et al.A microbial signature for Crohn's disease[J].Gut,2017,66(5):813-822.
[9] BAKHSHIMOGHADDAM F,ALIZADEH M.Modulation of the gut microbiota represents a new management for non-alcoholic fatty liver disease[J].HepatoBiliary Surg Nutr,2020,9(2):223-226.
[10] YADAV M,VERMA M,CHAUHAN N S.A review of metabolic potential of human gut microbiome in human nutrition[J].Arch Microbiol,2018,200(2): 203-217.
[11] BROWN C T,DAVIS-RICHARDSON A G,GIONGO A,et al.Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes[J/OL].PLoS One,2017,6(10)[2021-12-27].https://doi.org/10.1371/journal.pone.0025792.
[12] HARBISON J E,ROTH SCHULZE A J,GILES L C,et al.Gut microbiome dysbiosis and increased intestinal permeability in children with islet autoimmunity and type 1 diabetes:a prospective cohort study[J]. Pediatr Diabetes,2019,20(5):574-583.
[13] MA Q T,LI Y Q,WANG J K,et al.Investigation of gut microbiome changes in type 1 diabetic mellitus rats based on high-throughput sequencing[J/OL].Biomed Pharmacother,2020,124[2021-12-27].https://doi.org/10.1016/j.biopha.2020.109873.
[14] SIKALIDIS A K,MAYKISH A.The gut microbiome and type 2 diabetes mellitus:discussing a complex relationship[J/OL].Biomedicines,2020,8(1)[2021-12-27].https://doi.org/10.3390/biomedicines8010008.
[15] 肖瑶,牛玥,毛明慧,等.2型糖尿病与肠道核心菌群的相关性[J].南方医科大学学报,2021,41(3):358-369.
XIAO Y,NIU Y,MAO M H,et al.Correlation analysis between type 2 diabetes and core gut microbiota[J].J South Med Univ,2021,41(3):358-369.
[16] HU R X,YUAN Y T,LIU C L,et al.New insights into the links with anti-diabetes drugs and gut microbiota[J/OL].Endocr Connect,2020,10(1)[2021-12-27].https://doi.org/10.1530/EC-20-0431.
[17] KARLSSON F H,TREMAROLI V,NOOKAEW I,et al.Gut metagenome in European women with normal,impaired and diabetic glucose control[J].Nature,2013,498(7452):99-103.
[18] QIN J J,LI Y R,Cai Z M,et al.A metagenome-wide association study of gut microbiota in type 2 diabetes[J].Nature,2012,490:55-60.
[19] ZHU T T,GOODARZI M O.Metabolites linking the gut microbiome with risk for type 2 diabetes[J].Curr Nutr Rep,2020,9(2):83-93.
[20] BARTOSZEK A,MOO E V,BINIENDA A,et al.Free fatty acid receptors as new potential therapeutic target in inflammatory bowel diseases[J/OL].Pharmacol Res,2020,152[2021-12-27].https://doi.org/10.1016/j.phrs.2019.104604.
[21] XIA F,WEN L P,GE B C,et al.Gut microbiota as a target for prevention and treatment of type 2 diabetes:mechanisms and dietary natural products[J].World J Diabetes,2021,12(8):1146-1163.
[22] MARIALETIZIA R,CLAUDE K,CANI P D.Gut microbes and health:a focus on the mechanisms linking microbes,obesity,and related disorders[J].Obesity,2018,26(5):792-800.
[23] DUBOIS V,EECKHOUTE J,LEFEBVRE P,et al.Distinct but complementary contributions of PPAR isotypes to energy homeostasis[J].J Clin Invest,2017,127(4):1202-1214.
[24] AGUILAR E C,SILVA J F d,NAVIA-PELAEZ J M,et al.Sodium butyrate modulates adipocyte expansion,adipogenesis,and insulin receptor signaling by upregulation of PPAR-γ in obese ApoE knockout mice[J].Nutrition,2018,47(5):75-82.
[25] MASLOWSKI K,VIEIRA A,AYLWIN N,et al.Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43[J].Nature,2009,461:1282-1286.
[26] YANG Q Y,OUYANG J,SUN F J,et al.Short-chain fatty acids:a soldier fighting against inflammation and protecting from tumorigenesis in people with diabetes[J/OL].Front Immunol,2020[2021-12-27].https://doi.org/10.3389/fimmu.2020.590685.
[27] YU Z Q,YANG J Y,XIANG D,et al.Circadian rhythms and bile acid homeostasis:a comprehensive review[J].Chronobiol Int,2020,37(5):618-628.
[28] BOZADJIEVA N,HEPPNER K M,SEELEY R J.Targeting FXR and FGF19 to treat metabolic diseases-lessons learned from bariatric surgery[J].Diabetes,2018,67(9):1720-1728.
[29] IKEGAMI T,HONDA A.Reciprocal interactions between bile acids and gut microbiota in human liver diseases[J].Hepatol Res,2018,48(1):15-27.
[30] HE W,REBELLO O,SAVINO R,et al.TLR4 triggered complex inflammation in human pancreatic islets[J].Biochim Biophys Acta Mol Basis Dis,2019,1865(1):86-97.
[31] CANI P D,BIBILONI R,KNAUF C,et al.Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice[J].Diabetes,2008,57(6):1470-1481.
[32] GRAHAM C,MULLEN A,WHELAN K.Obesity and the gastrointestinal microbiota:a review of associations and mechanisms[J].Nutr Rev,2015,73(6):376-385.
[33] WANG G Q,LIU J,XIA Y J,et al.Probiotics-based interventions for diabetes mellitus:a review[J/OL].Food Biosci,2021,43[2021-12-27].https://doi.org/10.1016/j.fbio.2021.101172.
[34] ADESHIRLARIJANEY A,GEWIRTZ A T.Considering gut microbiota in treatment of type 2 diabetes mellitus[J].Gut Microbes,2020,11(3):253-264.
[35] TIDERENCEL K A,HUTCHEON D A,ZIEGLER J.Probiotics for the treatment of type 2 diabetes:a review of randomized controlled trials[J/OL].Diabetes/Metab Res Rev,2020,36(1)[2021-12-27].https://doi.org/10.1002/dmrr.3213.
[36] KOOTTE R S,LEVIN E,SALOJÄRVI J,et al.Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition[J].Cell Metab,2017,26(4):611-619.
[37] WANG H,LU Y,YAN Y,et al.Promising treatment for type 2 diabetes:fecal microbiota transplantation reverses insulin resistance and impaired islets[J/OL]. Front Cell Infect Microbiol,2019,9(5)[2021-12-27].https://doi.org/10.3389/fcimb.2019.00455.
[38] DE GROOT P,NIKOLIC T,PELLEGRINI S,et al.Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial[J].Gut,2020,70(1)92-105.
[39] GANESAN K,CHUANG S K,VANAMALA J,et al.Causal relationship between diet-induced gut microbiota changes and diabetes:a novel strategy to transplant Faecalibacterium prausnitzii in preventing diabetes[J/OL].Int J Mol Sci,2018,19(12)[2021-12-27].https://doi.org/10.3390/ijms19123720.
[40] VRIEZE A,VAN NOOD E,HOLLEMAN F,et al.Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome[J].Gastroenterology,2012,143(4):913-916.
[41] ZHAO L P,ZHANG F,DING X Y,et al.Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes[J].Science,2018,359(6380):1151-1156.
[1] 吴成慧, 彭艳红, 张可, 朱维晔, 邓亮, 谭玲玲, 瞿丹丹, 米秋香. 中青年2型糖尿病患者益处发现的影响因素分析[J]. 预防医学, 2026, 38(1): 31-35.
[2] 陆杰, 张柯, 吴雅, 王玥, 张玥, 陆叶, 吴周理, 任志华, 黄艺文. 肥胖指标预测2型糖尿病患者心脑血管疾病的效果比较[J]. 预防医学, 2025, 37(9): 886-891.
[3] 张凯慧, 李婉玲, 王彦兴, 安愿. 老年2型糖尿病患者心理灵活性、运动自我效能在衰弱与社会疏离间的中介效应分析[J]. 预防医学, 2025, 37(8): 783-788.
[4] 刘明坤, 张丰香, 韩彩静, 王霞, 陈世坤, 金梅, 孙金月. 2型糖尿病患者周围神经病变风险预测模型研究[J]. 预防医学, 2025, 37(7): 692-696.
[5] 胡瑜洁, 施新颜, 沈涌海, 周雅媛, 陈宇. 妊娠期肝内胆汁淤积症患者胆汁酸谱分析[J]. 预防医学, 2025, 37(7): 727-731.
[6] 俞丹丹, 杨加丽, 张雅萍, 许慧琳, 何丹丹, 李俊. 2型糖尿病共病患者空腹血糖波动轨迹的影响因素研究[J]. 预防医学, 2025, 37(6): 562-567,572.
[7] 何靖恺, 胡洁琼, 张加玏, 季蕴辛. 肠道菌群代谢产物与抑郁障碍研究进展[J]. 预防医学, 2025, 37(6): 583-587.
[8] 李美琳, 周梦姣, 吴佳芸, 喻喆, 孔利萍. 老年男性2型糖尿病患者合并肌少症的影响因素分析[J]. 预防医学, 2025, 37(6): 588-592.
[9] 陆丽君, 袁磊, 李殿江, 卢昆, 朱怡萱, 王志勇, 刘思浚. 老年2型糖尿病患者自我效能、自我管理行为在抑郁症状与血糖控制间的中介效应分析[J]. 预防医学, 2025, 37(5): 455-459.
[10] 史美琦, 殷玉华, 汪旭虹, 付元庆, 苗泽蕾, 胡文胜. 妊娠糖尿病孕妇植物性饮食模式与孕期体重增加的关联研究[J]. 预防医学, 2025, 37(5): 503-506.
[11] 王英杰 综述, 孙高峰, 审校. 2型糖尿病预测模型研究进展[J]. 预防医学, 2025, 37(4): 369-372,377.
[12] 李倩, 杨柏林, 陈积标, 尹寒露, 许祝平, 孟晓军. 无锡市50岁及以上HIV/AIDS抗病毒治疗病例自报慢性病资料分析[J]. 预防医学, 2025, 37(4): 390-394.
[13] 孙霞, 但玲英, 郑鹏, 陈薪伊. 2型糖尿病患者脂肪因子与糖尿病视网膜病变的关联研究[J]. 预防医学, 2025, 37(3): 248-252.
[14] 陈海苗, 马岩, 刘明奇, 马珊珊, 李军, 方益荣. 儿童期肥胖与2型糖尿病、冠心病的孟德尔随机化研究[J]. 预防医学, 2025, 37(3): 307-311.
[15] 俞丹丹, 张雅萍, 许慧琳, 何丹丹, 梁彤彤, 杨加丽, 李俊. 糖尿病共病患者自我管理行为与时间洞察力的关联研究[J]. 预防医学, 2025, 37(2): 130-134.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed